NCT06547775

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

A Randomized, Double-blind and Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 in Chinese Male Participants With Obesity or Overweight

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Suzhou Alphamab Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	KN069	Solution for SC injection

Timeline

• Start date: 2024-08-02
• Primary completion: 2027-04-30
• Completion: 2027-06-30
• First posted: 2024-08-09
• Last updated: 2025-09-17

Locations

1 site across 1 country: China